Trial Profile
A Phase I/II Study of Carfilzomib in Combination With R-CHOP (CR-CHOP) for Patients With Diffuse Large B-cell Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 04 Jan 2024
Price :
$35
*
At a glance
- Drugs Aciclovir (Primary) ; Carfilzomib (Primary) ; Cyclophosphamide (Primary) ; Doxorubicin (Primary) ; Filgrastim (Primary) ; Filgrastim (Primary) ; Pegfilgrastim (Primary) ; Prednisone (Primary) ; Rituximab (Primary) ; Vincristine (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions
- 12 Dec 2023 Results assessing the safety and efficacy of K in combination with R-CHOP (KR-CHOP) and the recommended phase 2 dose (RP2D) in all DLBCL patients, were presented at the 65th American Society of Hematology Annual Meeting and Exposition.
- 12 Jan 2022 Planned End Date changed from 1 Dec 2021 to 1 Dec 2022.
- 27 Jul 2021 Planned End Date changed from 1 Sep 2021 to 1 Dec 2021.